关注我们
Congratulations! Shendi Group’s strategic partner, Lisheng Bio, has completed a nearly 100-million-yuan Series A funding round.
Release time:
03 Jan,2025
On December 31, 2024, Shendi Group’s strategic partner, Liiying Bio, announced the completion of a new round of Series A funding totaling nearly 100 million yuan. This round of financing represents another milestone following two previous rounds of funding in the tens of millions yuan in 2023. Shendi Group extends its warmest congratulations on this exciting news!
On December 31, 2024, Shendi Group’s strategic partner, Liiying Bio, announced the completion of a new round of Series A funding totaling nearly 100 million yuan. This round of financing represents another milestone following two previous rounds of tens of millions of yuan in funding in 2023. Shendi Group extends its warmest congratulations on this exciting news!
Synthetic biology is a strategic, pioneering, and disruptive industry in China, representing a new type of productive force that is leading the world into a new round of technological revolution and industrial transformation. At the forefront of this wave, Lisheng Bio specializes in protein engineering and design, positioning itself as a trailblazer driving innovation in this field. Founded in 2022, the company leverages a foundation in structural biology and cutting-edge artificial intelligence computing to excel in protein design and modification. It provides high-quality, efficient R&D services and protein raw materials tailored to diverse protein application scenarios, committed to empowering industries across the board with advanced protein R&D capabilities.
Leveraging its robust innovation capabilities, Lisheng Bio has achieved numerous industry-leading breakthroughs in protein R&D, having already supported the development and scaled production of over 60 high-end proteins. These proteins are applicable to a variety of fields, including antibody engineering, industrial enzyme modification, enzymes for pharmaceutical intermediates, sweet-tasting proteins, and collagen. Among these, Lisheng Bio has made particularly groundbreaking progress in the field of recombinant collagen, successfully achieving the expression and purification of various types of triple-helical collagen in multiple expression systems—including E. coli, yeast, and mammalian cells. Moreover, Lisheng’s triple-helical collagen maintains the stability of its triple-helix structure even under high-temperature conditions, a world-first achievement in the industry. Additionally, Lisheng’s triple-helical collagen exhibits exceptionally strong cell-migration-promoting activity, enabling functions such as anti-aging, skin whitening, and wrinkle reduction. Its premium-tech skincare product, Tri-helix, has been certified by the internationally recognized SGS authority and has demonstrated a 40% reduction in the number of wrinkles within just 28 days. This product was also selected as one of the Top 10 New Products in Synthetic Biology Manufacturing for 2024 by “Zaowu.”
▲ Tri-helix, a high-end skincare product by Lisheng Bio-Technology
Recombinant collagen is a popular raw material in the field of synthetic biology. Driven by factors such as the continuous expansion of its applications in various products and improved market accessibility, it is now experiencing robust growth. Shendi Group has been actively involved in this field for a long time, and through 20 years of relentless investment in scientific research and technological development and commercialization, it has spearheaded technological breakthroughs and industrialization of its eggshell membrane and eggshell membrane collagen products.
▲ Shendi Group Eggshell Peptide TM Solid Beverage Product
The egg membrane is a fibrous film located between the eggshell and the egg white. It is rich in various bioactive substances, including numerous amino acids, collagen, glucosamine, chondroitin sulfate, hyaluronic acid, and functional peptides. With its exceptionally high nutritional value, extracting these small-molecule peptides from the egg membrane using modern technology represents an essential foundation for fully harnessing their nutritional benefits and therapeutic effects. Since 2008, Shendi Group has successively established R&D collaborations with universities such as Huazhong Agricultural University. In 2010, its related scientific and technological achievements were recognized as internationally advanced. In 2016, the group was awarded the First Prize for Technological Invention by Hubei Province. In 2018, a national invention patent was filed, and the project “Research, Development, and Industrialization of High-Value Comprehensive Utilization of Egg Membrane” was included in the National Key R&D Program during the 13th Five-Year Plan period. In 2019, the group’s egg membrane products made their debut at the inaugural World Health Expo, and CCTV-2 featured a special report on Shendi’s egg-source technological achievements. In 2022, a series of new products—including the egg membrane peptide TM solid beverage—were further iteratively upgraded, leveraging the egg membrane’s proven benefits in joint repair, beauty enhancement, and anti-aging, and quickly gained widespread market acclaim. In 2024, Shendi Group played a key role in drafting and issuing the group standard “Egg Membrane Peptides,” marking another significant milestone.
▲ Shendi Group’s invention patents related to eggshell membranes
In 2023, Shendi Group and Lijing Bio officially established a comprehensive strategic partnership to jointly build a research center for eggshell membrane recombinant proteins. This marks an important step for Shendi Group in the development and utilization of eggshell membranes. Both parties possess outstanding strengths in their respective fields, while also having vast potential for collaboration and significant future market growth. Together, they are committed to working hand in hand and jointly creating new breakthroughs in life and health.
▲ Shendi Group and Lijing Bio Co., Ltd. Jointly Establish a Chicken Egg Membrane Recombinant Protein Research Center
Once again, we extend our warmest congratulations to Grain Shadow Bio on the successful completion of this round of financing. This funding will serve as a powerful accelerator for Grain Shadow Bio’s technological innovation and commercialization efforts, and will also inject tremendous momentum into the rapid development of synthetic biology, as well as groundbreaking innovations and applications in recombinant collagen. Standing at the forefront of life sciences, Shendi Group will continue to collaborate closely with Grain Shadow Bio and work together with an even broader array of industry partners to continuously explore new frontiers in the development and utilization of eggshell membranes and eggshell collagen. By harnessing the power of technology, we will fully unlock the “membrane potential,” vigorously drive the industry’s leapfrog development, and deliver more scientifically sound and professionally crafted health products and experiences to consumers.
Related News
Telephone:
E-mail:bd@hbsd.cn
Address: Shendi Industrial Park, Jingshan Economic Development Zone, Jingmen City, Hubei Province
Shendi Group
Eggbio
PAPAMENG
Shendi Qidan
Shendi Mall